FDA approval: Siltuximab for the treatment of patients with multicentric castleman disease

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 950-954

  Deisseroth, Albert ^a   Ko, Chia Wen ^a   Nie, Lei ^a   Zirkelbach, Jeanne F ^a   Zhao, Liang ^a   Bullock, Julie ^a   Mehrotra, Nitin ^a   Del Valle, Pedro ^a   Saber, Haleh ^a   Sheth, Christopher ^a   Gehrke, Brenda ^a   Justice, Robert ^a   Farrell, Ann ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CORTICOSTEROID; DRUG ANTIBODY; HEMOGLOBIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; PLACEBO; SILTUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPIGMENTATION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOTENSION; INFUSION RELATED REACTION; KIDNEY FAILURE; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; MULTICENTRIC CASTLEMAN DISEASE; NONHUMAN; OROPHARYNX PAIN; PLASMA HALF LIFE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; ADULT; AGED; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GIANT LYMPH NODE HYPERPLASIA; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84926516718     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1678     Document Type: Article

References (12)

1. Castleman B, Towne VW. Case records of the Massachusetts general hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954; 251: 396-400.
2. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J of Hematol 2012; 87: 997-1002.
3. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: anupdateondiagnosis, assessment and therapy. Clin Adv Hematol Oncol 2010; 8: 486-98.
4. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004; 43: 698-704.
5. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128: 657-62.
6. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-9.
7. Soulier J, Groller L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Bibinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-80.
8. Frizzera G, Banks PM, Massarelli G, Rossai J. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 1983; 7: 211-31.
9. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106: 2627-32.
10. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659-70.
11. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15: 966-74.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.